Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLoans and Notes ReceivablesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Accumulated Depreciation & Amortization (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Accumulated Depreciation & Amortization over the past 15 years, most recently at $8.0 million for Q2 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $8.0 million for Q2 2025, up 0.92% from a year ago — trailing twelve months through May 2025 was $8.0 million (up 0.92% YoY), and the annual figure for FY2025 was $8.0 million, up 0.92%.
  • Accumulated Depreciation & Amortization for Q2 2025 was $8.0 million at Lifecore Biomedical, Inc. \De\, up from $2.1 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for LFCR hit a ceiling of $19.9 million in Q2 2021 and a floor of $2.0 million in Q3 2024.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $7.6 million (2022), compared with a mean of $8.3 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 5.46% in 2021 and later crashed 80.91% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Accumulated Depreciation & Amortization stood at $11.0 million in 2021, then plummeted by 33.65% to $7.3 million in 2022, then tumbled by 46.07% to $3.9 million in 2023, then tumbled by 48.04% to $2.0 million in 2024, then soared by 292.71% to $8.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $8.0 million (Q2 2025), $2.1 million (Q1 2025), and $2.0 million (Q4 2024) per Business Quant data.